CARLSBAD, Calif., May 27, 2021 (GLOBE NEWSWIRE) — Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced FDA approval for the company to initiate its Atrial Fibrillation (“AF”) Investigational Device Exemption (IDE) clinical trial for the AcQBlate Force Sensing Ablation Catheter and System. […]
Tag: AcQBlate
Acutus Medical Initiates First IDE Therapy Trial with the AcQBlate® FORCE Sensing Ablation System
CARLSBAD, Calif., April 05, 2021 (GLOBE NEWSWIRE) — Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced initial US enrollments in the company’s AcQForce™ Flutter Investigational Device Exemption (IDE) clinical trial. This trial is expected to enroll up to 150 subjects in leading […]
Acutus Medical Launches AcQBlate® Force Sensing Ablation System in Europe
Gold-Tipped Force Sensing Ablation Catheter Earns CE Mark, Expanding Acutus’ Comprehensive Electrophysiology Portfolio CARLSBAD, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) — Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the launch of the AcQBlate® Force Sensing Ablation System in Europe after securing CE Mark for […]